-
ENABLING HEALTH TECHNOLOGY ASSESSMENT (HTA) TA READINESS THROUGH REAL-TIME AI-ASSISTED LIVING SYSTEMATIC LITERATURE REVIEWS (REAL-SLR): A BREAST CANCER (BCA) CASE STUDY
Mar 18, 2026, 21:38 PM -
AI-ASSISTED APPROACHES FOR DEFINING LINES OF THERAPY IN ONCOLOGY REAL-WORLD DATA: AN EXPLORATORY ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF SUBCUTANEOUS MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN VERSUS RITUXIMAB PLUS GEMCITABINE AND OXALIPLATIN FOR UNITED STATES (US) PATIENTS WITH AUTOLOGOUS STEM CELL TRANSPLANT-INELIGIBLE RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
Mar 18, 2026, 21:38 PM -
ASSOCIATION OF FATIGUE AND ACUTE PAIN WITH HEALTH CARE RESOURCE UTILIZATION AND COSTS IN SICKLE CELL DISEASE IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
USE OF REAL-WORLD EVIDENCE ON US BRANDED HCP DRUG WEBSITES: AN AI-ENABLED CONTENT ANALYSIS
Mar 18, 2026, 21:38 PM -
TEMPORAL TRENDS AND DETERMINANTS OF AORTIC VALVE REPLACEMENT IN PATIENTS WITH ASYMPTOMATIC SEVERE AORTIC STENOSIS
Mar 18, 2026, 21:38 PM -
PROJECT ORBIS: DOES REGULATORY ACCELERATION TRANSLATE TO FASTER GLOBAL PATIENT ACCESS?
Mar 18, 2026, 21:38 PM -
COST COMPARISON OF ATEZOLIZUMAB IN CANADA FOR THE FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER PATIENTS WITH HIGH PROGRAMMED DEATH-LIGAND 1 EXPRESSION
Mar 18, 2026, 21:38 PM -
DISTANCE FROM HEALTH CARE FACILITY AND OTHER VARIABLES IMPACT TIME TO CELIAC DISEASE DIAGNOSIS
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF LAZERTINIB-AMIVANTAMAB COMPARED TO OSIMERTINIB FOR NON-SMALL CELL LUNG CANCER: A 5-YEAR PARTITIONED SURVIVAL MODEL
Mar 18, 2026, 21:38 PM -
INCORPORATING SPILLOVER EFFECTS IN COST-EFFECTIVENESS ANALYSIS: A CASE STUDY FOR FIRST LINE TREATMENT OF METASTATIC (STAGE IV) NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
Mar 18, 2026, 21:38 PM -
COULD OPERATING-ROOM TIME DIFFERENCES FOR LITHOTRIPSY BE AN INDICATOR OF HEALTHCARE ACCESS?
Mar 18, 2026, 21:38 PM -
COMPARING INFECTION OUTCOMES AND ANTIBIOTIC USE IN ADMINISTRATIVE CLAIMS FOLLOWING CYSTOURETHROSCOPY WITH SINGLE USE VERSUS REUSABLE SCOPES
Mar 18, 2026, 21:38 PM -
WHEN ADHERENCE ESTIMATES DIFFER: THE IMPACT OF DATA SOURCE AND GAP HANDLING IN REAL-WORLD MEDICATION USE ASSESSMENT
Mar 18, 2026, 21:38 PM -
COMPARISON OF SAMPLING STRATEGIES TO ADDRESS SEVERE DATA IMBALANCE AND COMPUTATIONAL BENCHMARKING FOR TIME-TO-EVENT PREDICTIVE MODEL DEVELOPMENT ACROSS LOCAL AND HIGH-PERFORMANCE COMPUTING ENVIRONMENTS: PREDICTION OF ALCOHOL USE DISORDER AND OPIOID...
Mar 18, 2026, 21:38 PM -
SIX MONTH OUTCOMES AND GLUCAGON-LIKE PEPTIDE-1 (GLP-1) THERAPY PERSISTENCE AMONG COMMERCIALLY INSURED ADULTS WITHOUT DIABETES IN AN OBESITY CARE MANAGEMENT PROGRAM
Mar 18, 2026, 21:38 PM -
TERMINAL CARE COSTS IN JAPAN USING LINKED HEALTH AND LONG-TERM CARE CLAIMS: WHICH IS MORE EXPENSIVE—HOSPITAL DEATH OR LONG-TERM CARE FACILITY DEATH?
Mar 18, 2026, 21:38 PM -
DIGITAL CAREGIVER TRAINING FOR PROMOTING FUNCTIONAL INDEPENDENCE AND HEALTHY AGING
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF PRECISION SCREENING FOR ATRIAL FIBRILLATION: A DECISION-ANALYTIC MODEL
Mar 18, 2026, 21:38 PM -
THE DIABETES PENALTY, ARE WE COMPARING LIKE VERSUS LIKE IN OBESITY MANAGEMENT? RE-RANKING SEMAGLUTIDE AND TIRZEPATIDE AFTER ADJUSTING FOR COMORBID T2D CONFOUNDING
Mar 18, 2026, 21:38 PM
